# Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide

> **NCT01282216** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 120 (actual)

## Conditions studied

- Transplant-Related Cancer

## Interventions

- **BIOLOGICAL:** Havrix
- **BIOLOGICAL:** PCV13

## Key facts

- **NCT ID:** NCT01282216
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-04
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 120 (ACTUAL)
- **Why stopped:** Low accrual and loss of funding.
- **Last updated:** 2019-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01282216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01282216, "Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01282216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*